Straits Times Index
3,073.64 -13.60 (-0.44%) S&P 500
4,549.34 -17.84 (-0.39%) Dow
36,054.43 -70.17 (-0.19%) Nasdaq
14,146.71 -83.19 (-0.58%) Bitcoin USD
43,238.91 -526.51 (-1.20%) CMC Crypto 200
882.39 +639.71 (+263.61%)
BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
- GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares, and restricted stock units (RSUs) covering an aggregate of 51,050 shares, of BioCryst common stock. The options and RSUs were granted as of November 30, 2023, as inducements material to each employee entering into emplo
- GlobeNewswire
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We continue to make strides to bring ORLADEYO to patients living with HAE in Latin America in col
- GlobeNewswire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in Miami at 9:35 a.m. ET and the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29th in New York at 12:30 p.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst
